Health TrialsbyHealthPanel

Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)

ConditionsAtrial FibrillationIntracardiac Thrombus
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorFirst Affiliated Hospital Xi'an Jiaotong University

About this trial

This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years old, age ≤80 years old

Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter

Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy

Disqualifiers

Echocardiography confirmed valvular heart disease

Contraindications to anticoagulants

Patients with the previous history of hemorrhagic stroke

Low platelet count or functional platelet defects

Trial population

Patients with non-valvular atrial fibrillation who have been diagnosed with intracardiac thrombosis by First Affiliated Hospital of Xi'an Jiaotong University and multiple medical centers, meet the indications for anticoagulation therapy, and are willing to receive anticoagulation therapy.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Observational; No Interventions were given.

    Other intervention

    Observational; No Interventions were given.

Treatment groups

500 Participants
are divided into 2 treatment groups
Group A: Experimental group1 intervention
Group B: Control group1 intervention

Trial outcomes

Primary outcomes

1

Success rate of thrombolysis

Success rate of thrombolysis within 3 months after initiating anticoagulation therapy.

Time frame
1，2，3 months after enrollment.
2

Change of incidence of MACCE

Major adverse cardiovascular and cerebrovascular events, a composite of all-cause mortality, myocardial infarction, coronary revascularization, and stroke.

Time frame
1，2，3 months after enrollment.

Secondary outcomes

1

Change of incidence of adverse anticoagulation events

Bleeding and thrombotic events

Time frame
1，2，3 months after enrollment.
2

Change of incidence of all-cause mortality

All-cause mortality diagnosed by clinical doctors.

Time frame
1，2，3 months after enrollment.
3

Change of incidence of myocardial infarction

Myocardial infarction diagnosed by clinical doctors.

Time frame
1，2，3 months after enrollment.
4

Change of incidence of coronary revascularization

Coronary revascularization assessed by clinical doctors.

Time frame
1，2，3 months after enrollment.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

First Affiliated Hospital Xi'an Jiaotong University

Lead sponsor

521 Hospital of NORINCO Group

Collaborator

Shaanxi Provincial People's Hospital

Collaborator

Xiangyang Central Hospital

Collaborator

Henan Provincial People's Hospital

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: